And this pipeline is addressing clinical activity in serious unmet medical needs, advanced pancreatic cancer, lung COVID, advanced recurrent ovarian cancer, stage 4 triple negative breast cancer. For a company of our size, very few can boast of the accomplishments that we've made as well as the pipeline that we have in place right now. So this 2022 activity that's referenced here is our foundation for springing forward in 2023. When you go to publications regarding Ampligen or rintatolimod, you'll see we are regularly publishing papers through independent researchers and top institutions outlining data that shows the potential, the great potential for Ampligen. Our progress is evidenced by the 20 some things you see referenced here that have occurred in 2022. Now we are unique in many respects for a company of our size because we have an extremely robust pipeline, we have had a large number of material and significant accomplishments. You also see that our social media imprint is stronger and being expanded consistent with the work we're doing on our website. And we intend starting with this presentation today and quarterly hereafter to have earnings calls to discuss our progress, as well as our plans for the future. Communicating frequently with our stockholders remains a top priority. Over the course of 2022, we focused on improving communications. We invite all of you to come and visit our website and see what we've done and where we're going. In addition to this progress, our outreach and our desire to properly communicate our progress as well as our plans is enhanced by the launch of our new website. These are lethal unmet medical needs, some of which are in extremely large market opportunities. We've built an extremely robust pipeline in high-value indications. But you will also see how we are transitioning ourselves into late stage clinical immuno-pharma development utilizing our lead program, Ampligen. Now you will see that we have made tremendous progress over the course of 2022 as we go forward. And we look forward to showing you today how, over the past year and going forward, we intend to live up to that model by developing immunological solutions for serious unmet medical needs. As a reminder, our motto at AIM ImmunoTech is immunology for a better future. We look forward to reviewing today our many achievements on the operational, clinical and regulatory fronts. Today marks an important time in our evolution. Thank you, everyone, for your interest in AIM ImmunoTech, and welcome to our inaugural earnings call. I'd now like to turn the conference over to Thomas Equels, Chief Executive Officer. Joining us on today's call from AIM ImmunoTech leadership team are Thomas Equels, Chief Executive Officer and Chris McAleer, Ph.D. While the company believes these third party resources to be reliable as of the date of this presentation, is not independently verified and makes no representation as to the accurate adequacy, fairness accuracy or completeness of or that any independent source has verified any information obtained from third party sources. We encourage you to review these documents carefully.Īdditionally, certain information contained in this webcast relates to or is based on studies, publication, surveys and other data obtained from third party sources and the company's own estimates and research. These documents are available on the Investors section of the company's website and on the Securities and Exchange Commission's website. Some of the factors that could cause actual results to differ materially from these contemplated by such forward looking statements are discussed in the periodic reports AIM ImmunoTech files with the Securities and Exchange Commission. As a result, you should not place undue reliance on any forward looking statements. Forward looking statements on this call are made pursuant to the Safe Harbor provisions of the federal securities laws that are based on AIM ImmunoTech's current expectations and actual results could differ materially. These are forward looking statements and involve risks and uncertainties. Note that this webcast is being recorded at the company's request and a replay will be made available on the company's website following the end of the event.Īt this time, I'd like to remind our listeners that remarks made during this webcast may state management's intentions, beliefs, expectations or future projections. Following the presentation, there will be a question-and-answer session. As a brief reminder, all participants are currently in a listen-only mode. Hello, and welcome to the AIM ImmunoTech Inaugural Fiscal Year 2022 Update Conference Call and Webcast. ( NYSE: AIM) Q4 2022 Earnings Conference Call Ap8:30 AM ET
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |